The Regenerative Effect of Bone Marrow-Derived Stem Cells on Cell Count and Survival in Acute Radiation Syndrome

Seyed Mahmood Reza Aghamir¹, Davood Mehrabani², Masoud Amini³, Mohammad Amin Mosleh-Shirazi⁴, Samaneh Nematolah⁵, Fatemeh Shekoohi-Shooli¹, Seyed Mohammad Javad Mortazavi⁶, Iman Razeghan Jahromi²

DEAR EDITOR

Acute radiation syndrome (ARS) is called as radiation sickness or radiation toxicity caused by abnormally high exposure to ionizing radiation in a very short period of time.¹ High doses of ionizing radiation are able to contribute to detrimental systemic effects in different organs.² In treatment of patients with ARS, physicians have used growth factors, cytokines and bone marrow transplantation.³ Mesenchymal stem cells (MSCs) have the potential for multilineage differentiation.⁴,⁵ Bone marrow-derived stem cells (BMSCs) are the most well-known type of the mesenchymal stem cells used with safety and efficacy in several diseases such as ARS.¹ The present study assessed the regenerative effect of bone marrow-derived stem cells on cell count and survival in Acute Radiation Syndrome.

For MSC culture, both femoral and tibial bones from male mice were removed and after removal of muscular and connective tissues, the bones were cut at both ends and the bone marrow was flushed out into a 15 ml falcon tube filled with Dulbecco’s Modified Eagle Medium (DMEM; Biovet, Bulgaria) and 1% penicillin streptomycin (Sigma, USA) and centrifuged at 1200 rpm for 5 minutes. The precipitate was cultured in 25 cm² flasks containing DMEM supplemented with 10% fetal bovine serum (FBS; Biovet, Bulgaria), 1% L-glutamine (Sigma, USA) and 1% penicillin and streptomycin. The culture flasks were transferred into CO₂ incubator while the medium was changed every 3 days. The adherent cells were subcultured until passage 5 while they were counted for survival rate. The osteogenic was evaluated with Alizarin Red staining (Sigma, USA). RT-PCR was conducted to evaluate the expression of MSC markers. Forty 8-12 weeks male mice were randomly divided into 2 equal groups. Group A received no BMSCs but group B underwent 150×10³ cells of passage 5 in 150 µl medium of BMSC transplantation intravenously into the tail, 24 hours after γ irradiation. Both groups were irradiated with 10 Gy (dose rate .286 Gy/ min) ⁶⁰⁰CO, during 35 minutes with a field size of 35×35 for all the body area.

BMSCs were plastic adherent and spindle-shape (Figure 1) and expressed CD90 marker but not CD34 and CD45 (Figure 2). Culture of BMSCs in osteogenic media lead to osteogenic differentiation of these cells (Figure 3). A significant increase was noticed for the number cells in bone marrow in group B.

*Co-Corresponding Authors:
Fatemeh Shekoohi-Shooli, MSc; MSc student of Radiobiology and Radiation Protection of Department of Radiology and Radiotherapy, School of Paramedical, Shahid Beheshti University of Medical Sciences, Tehran, Iran
E-mail: f.shekoohi@sbmu.ac.ir
Seyed Mohammad Javad Mortazavi, PhD;
Professor of Medical Physics, Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
E-mail: mmortazavi@sums.ac.ir
Received: February 1, 2016
Revised: April 30, 2016
Accepted: May 10, 2016
Survival in acute radiation syndrome

when compared to group A, one week after γ irradiation \((p=0.0001, \text{ Table 1})\). The mortality rate one and two weeks after γ irradiation was demonstrated in Table 2.

BMSCs were shown to differentiate into various cells, and secrete cytokine and growth factors, and have immunomodulatory properties through paracrine and endocrine mechanisms in injured tissue. Eaton et al. showed that MSC therapy can be effective for acute radiation syndrome due to the fact that MSCs have immunomodulatory properties. Guo et al. in a 32-year-old man who was exposed to whole body dose of 14.5 GY γ - radiation concluded that cell therapy was an effective approach and significantly decreased mortality rate. Lange et al. found that systemic administration of MSCs had healing effects in ARS and managed radiation. Chapel et al. revealed that MSCs can migrate to the site of injury and repair the injured tissue. The therapeutic use of compact of BMSCs was shown to reduce the injury and increase the survival rate after lethal whole body irradiation. These studies confirm our findings demonstrating that BMSCs reduced the detrimental effects of radiation and increased the survival rate in ARS. Based on our findings, BMSCs can be recommended in reduction of detrimental effects of ARS and decreasing the mortality after exposure to γ irradiation.

**ACKNOWLEDGEMENTS**

This work was supported by Stem Cell and Transgenic Technology Research Center, Shiraz.

**Table 1:** Cell count in bone marrow one week after γ irradiation.

<table>
<thead>
<tr>
<th>Variable</th>
<th>No.</th>
<th>Cell count of bone marrow (Mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A (no receive BM-MSCs)</td>
<td>6</td>
<td>(1.77\times10^7±20\times10^6)</td>
</tr>
<tr>
<td>Group B (receive BM-MSCs)</td>
<td>6</td>
<td>(2.47\times10^7±2\times10^6)</td>
</tr>
<tr>
<td>(p) value</td>
<td></td>
<td>0.0001</td>
</tr>
</tbody>
</table>
University of Medical Sciences, Shiraz, Iran. Authors also wish thanks the support Leo E Gerweck.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

KEYWORDS

Acute radiation syndrome; Mesenchymal stem cells; Bone marrow; Survival; Cell count

Please cite this paper as:

REFERENCES